Literature DB >> 8241092

Familial hypoalphalipoproteinemia in premature coronary artery disease.

J Genest1, J M Bard, J C Fruchart, J M Ordovas, E J Schaefer.   

Abstract

Hypoalphalipoproteinemia (HA) is a common finding in patients with premature coronary artery disease. To characterize the common familial forms of HA, we studied 102 families of probands with premature coronary artery disease; 40 probands (39.2%) had HA. Of these, 25 had at least one first-degree relative affected with HA; 11 had familial hypertriglyceridemia with HA (FTgHA); 10 had familial combined hyperlipidemia (FCH); and 4 had familial HA (FHA) with no other lipoprotein abnormalities. In the remaining 15 families, no lipoprotein abnormalities were observed in first-degree relatives. We measured apolipoprotein (apo) A-I, B, C-III, and E levels as well as lipoprotein particle (Lp) levels of LpA-I (containing apoA-I only), LpA-I:A-II (containing both apoA-I and A-II), LpB:E, and LpB:C-III. Compared with a reference group of healthy men (n = 103) and women (n = 106), probands with familial forms of HA had lower high-density lipoprotein cholesterol levels by selection criteria. Triglyceride levels were higher in FTgHA and FCH probands than in the reference group or FHA subjects. Despite selection of FTgHA and FCH by low-density lipoprotein (LDL) cholesterol, the latter was not significantly different between the three groups and the reference group. ApoA-I levels were decreased in FCH, FHA, and FTgHA probands, and LpA-I and LpA-I:A-II were lower in FHA and FTgHA probands. ApoB levels were significantly higher in all familial HA groups compared with the reference group, being highest in FCH individuals, but not significantly higher between FCH, FTgHA, or FHA probands. LpB:E levels were higher in the FCH and FTgHA groups than in the reference group. There were no significant differences between groups for apoE, apoC-III, and LpB:C-III. LDL particle size was smaller in all three forms of FHA, which, in combination with higher apoB levels, reflects an increased number of smaller, denser LDL particles. Affected children had, on average, higher apoB and LpB:E levels than nonaffected siblings. Our data suggest that common forms of FHA in subjects with coronary artery disease represent a spectrum of overlapping disorders characterized by an increase in apoB-containing lipoproteins, especially LpB:E particles, and smaller, denser LDL particles. When using appropriate age- and gender-adjusted cutpoints, approximately half the offspring (in young adulthood) appeared to be affected.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241092     DOI: 10.1161/01.atv.13.12.1728

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  21 in total

1.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

2.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 3.  High-density lipoprotein subfractions and risk of coronary artery disease.

Authors:  John Morgan; Christina Carey; Anne Lincoff; David Capuzzi
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

Review 4.  Genetic causes of high and low serum HDL-cholesterol.

Authors:  Daphna Weissglas-Volkov; Päivi Pajukanta
Journal:  J Lipid Res       Date:  2010-04-26       Impact factor: 5.922

Review 5.  HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease.

Authors:  H Bryan Brewer
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

6.  Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics.

Authors:  Linhong Jing; Carol E Parker; David Seo; Maria Warren Hines; Nedyalka Dicheva; Yanbao Yu; Debra Schwinn; Geoffrey S Ginsburg; Xian Chen
Journal:  Proteomics       Date:  2011-06-17       Impact factor: 3.984

7.  Hypercholesterolemia and Dyslipidemia: Issues for the Clinician.

Authors:  H. Robert Superko; Nicolas A. Chronos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-02

8.  The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia.

Authors:  Liam R Brunham; Kelsey Lynch; Amy English; Rory Sutherland; Jian Weng; Raymond Cho; Graham C Wong; Aslam H Anis; Gordon A Francis; Nadia A Khan; Bruce McManus; David Wood; Keith R Walley; Jonathon Leipsic; Karin H Humphries; Alison Hoens; Andrew D Krahn; G B John Mancini; Simon Pimstone
Journal:  Clin Cardiol       Date:  2018-06-11       Impact factor: 2.882

Review 9.  Diagnosis and treatment of high density lipoprotein deficiency.

Authors:  Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos
Journal:  Prog Cardiovasc Dis       Date:  2016-08-24       Impact factor: 8.194

Review 10.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.